Search results
Results from the WOW.Com Content Network
The main classes of antiviral drugs used against influenza are neuraminidase inhibitors, such as zanamivir and oseltamivir, polymerase acidic endonuclease inhibitors such as baloxavir marboxil, or inhibitors of the viral M2 protein, such as amantadine and rimantadine. These drugs can reduce the severity of symptoms if taken soon after infection ...
Echoviruses are a cause of many of the nonspecific viral infections that can range from minor illness to severe, potentially fatal conditions such as aseptic meningitis, encephalitis, paralysis and myocarditis. [13] It is mainly found in the intestine, and can cause nervous disorders. [14]
viral RNA polymerase inhibitor Moroxydine: Influenza Nelfinavir: HIV Nirmatrelvir/ritonavir (Paxlovid) COVID-19: Pfizer: 3C-like protease inhibitor (Nirmatrelvir) / inhibition of metabolism of nirmatrelvir (ritonavir) Nevirapine: HIV non-nucleoside reverse transcriptase inhibitor: Nitazoxanide: Broad-spectrum antiviral: thiazolide Norvir: HIV ...
A viral disease (or viral infection) occurs when an organism's body is invaded by pathogenic viruses, and infectious virus particles (virions) attach to and enter susceptible cells. [ 1 ] Examples are the common cold , gastroenteritis , corona , flu , pneumonia .
Treatment of influenza in cases of mild or moderate illness is supportive and includes anti-fever medications such as acetaminophen and ibuprofen, adequate fluid intake to avoid dehydration, and resting at home. Under research [24] Yes: Isospora belli: Isosporiasis: Microscopic demonstration of the large typically shaped oocysts is the basis ...
Oncolytic virotherapy is not a new idea – as early as the mid 1950s doctors were noticing that cancer patients who suffered a non-related viral infection, or who had been vaccinated recently, showed signs of improvement; [3] this has been largely attributed to the production of interferon and tumour necrosis factors in response to viral infection, but oncolytic viruses are being designed ...
Nirmatrelvir/ritonavir has been evaluated in the treatment of COVID‑19 in standard-risk individuals in the EPIC-SR trial. [53] [55] This study did not achieve its primary goal of reducing time to sustained alleviation of COVID‑19 symptoms (treatment: 13 days (95% CI 12–15 days); placebo: 13 days (95% CI 11–14 days)).
Many viral vertically transmitted infections have no effective treatment, but some, notably rubella and varicella-zoster, can be prevented by vaccinating the mother prior to pregnancy. [citation needed] Pregnant women living in malaria-endemic areas are candidates for malaria prophylaxis.